Barry P Flannelly Incyte Corp (INCY) insider trading activity

Barry P Flannelly is EVP & General Manager US of INCYTE CORP. Currently has a direct ownership of 35,149 shares of INCY, which is worth approximately $2.87 Million. The most recent transaction as insider was on Jul 16, 2025, when has been sold 1,340 shares (Common Stock) at a price of $68.36 per share, resulting in proceeds of $91,602. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 35.1K

41.13% 3M change

39.44% 12M change

Total Value Held $2.87 Million

Barry P Flannelly Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jul 16 2025	SELL Open market or private sale	$91,602 $68.36 p/Share	1,340 Reduced 3.67%	35,149 Common Stock
Jul 15 2025	SELL Payment of exercise price or tax liability	$77,873 $68.25 p/Share	1,141 Reduced 3.03%	36,489 Common Stock
Jul 15 2025	SELL Open market or private sale	$83,273 $69.86 p/Share	1,192 Reduced 3.07%	37,630 Common Stock
Jul 14 2025	SELL Payment of exercise price or tax liability	$64,521 $69.98 p/Share	922 Reduced 2.32%	38,822 Common Stock
Jul 03 2025	SELL Open market or private sale	$743,039 $68.15 p/Share	10,903 Reduced 21.53%	39,744 Common Stock
Jul 02 2025	SELL Payment of exercise price or tax liability	$617,279 $68.17 p/Share	9,055 Reduced 15.17%	50,647 Common Stock
Apr 01 2025	BUY Grant, award, or other acquisition	-	26,135 Added 30.45%	59,702 Common Stock
Mar 14 2025	SELL Open market or private sale	$1,342,914 $67.8 p/Share	19,807 Reduced 37.11%	33,567 Common Stock
Jan 15 2025	SELL Payment of exercise price or tax liability	$228,828 $72.46 p/Share	3,158 Reduced 5.59%	53,374 Common Stock
Dec 09 2024	SELL Payment of exercise price or tax liability	$108,886 $72.11 p/Share	1,510 Reduced 2.6%	56,532 Common Stock
Nov 06 2024	SELL Open market or private sale	$294,804 $80.11 p/Share	3,680 Reduced 5.96%	58,042 Common Stock
Nov 06 2024	BUY Exercise of conversion of derivative security	$259,256 $70.45 p/Share	3,680 Added 5.63%	61,722 Common Stock
Jul 16 2024	SELL Open market or private sale	$83,832 $64.19 p/Share	1,306 Reduced 2.2%	58,042 Common Stock
Jul 15 2024	SELL Payment of exercise price or tax liability	$71,381 $64.25 p/Share	1,111 Reduced 1.84%	59,348 Common Stock
Jul 15 2024	BUY Grant, award, or other acquisition	-	9,925 Added 14.1%	60,459 Common Stock
Jul 09 2024	SELL Open market or private sale	$488,880 $60.0 p/Share	8,148 Reduced 13.89%	50,534 Common Stock
Jul 02 2024	SELL Payment of exercise price or tax liability	$454,158 $59.02 p/Share	7,695 Reduced 11.59%	58,682 Common Stock
Jun 12 2024	SELL Open market or private sale	$1,149,840 $60.0 p/Share	19,164 Reduced 22.4%	66,377 Common Stock
Feb 14 2024	BUY Grant, award, or other acquisition	-	7,377 Added 7.98%	85,080 Common Stock
Jan 17 2024	SELL Payment of exercise price or tax liability	$225,939 $61.48 p/Share	3,675 Reduced 4.52%	77,703 Common Stock
Jul 14 2023	BUY Grant, award, or other acquisition	-	9,668 Added 10.62%	81,378 Common Stock
Jul 03 2023	SELL Payment of exercise price or tax liability	$391,352 $62.08 p/Share	6,304 Reduced 8.08%	71,710 Common Stock
Jan 20 2023	BUY Grant, award, or other acquisition	-	4,980 Added 6.03%	77,654 Common Stock
Jul 07 2022	SELL Open market or private sale	$228,059 $79.38 p/Share	2,873 Reduced 3.8%	72,674 Common Stock
Jul 05 2022	SELL Payment of exercise price or tax liability	$277,850 $79.25 p/Share	3,506 Reduced 4.43%	75,547 Common Stock

Also insider at

TARA

Protara Therapeutics, Inc. Healthcare

BPF